Drug Discovery & Development’s Post

AI drug discovery space consolidates with $688M Recursion and Exscientia merger The merger of Recursion and Exscientia would create one of the largest AI-based pipelines in the industry, with several drug candidates in advanced stages of clinical development. The combined company aims to have 10 clinical readouts over the next 18 months, with potential peak sales opportunities surpassing $1 billion. https://lnkd.in/gSJ3R5cY